Pakistani firm to market Indian cancer drug

Published
0

RAWALPINDI, Feb 1: A Pakistani pharmaceutical company has entered into an agreement with an Indian firm to market locally a drug used for the treatment of head and neck cancer.

The licensing deal was signed between Ferozsons Laboratories of Pakistan and Biocon of India.

With the signing of the agreement for local marketing of cancer drug “Biomab EGFR”, Pakistan has become the second country in the Saarc region after India where the “best in class cancer drug” is being launched. The medicine was launched in India two months ago.

Biomab EGFR, a monoclonal antibody product, is prescribed for the treatment of head and neck cancer and is being studied in global clinical trials for colorectal, lung cancer, Glioma and pancreatic cancers. The product developed by the Cuba’s Centre for Treatment of Immunology is being commercialised in the region by Biocon under a joint venture.

Head and neck cancer is among the major cancers in Pakistan because of excessive use of tobacco and betel nut in the country. About 25,000 new cases of head and neck cancer are diagnosed every year in the country. The drug has shown remarkable results in clinical studies conducted in various countries, including Canada and the United States, and has been granted accelerated orphan status registration by the EU authorities.

Osman Khalid Waheed, president of Ferozsons Laboratories, said: “We view this agreement with Biocon as an important milestone towards achieving our vision of becoming a complete provider of medicine for cancer treatment. Monoclonal antibodies are emerging as the most important new class of drugs in cancer therapy. With this alliance, we are confident that we will make a substantial contribution to the treatment of head and neck and other cancers in Pakistan by providing cutting-edge, targeted therapy at an affordable cost for patients in Pakistan.”

Dr Kiran Mazumdar-Shaw, Chairman of Biocon (India), said: “Our partnership with Ferozsons for ‘Biomab EGFR’ heralds our efforts in extending the benefit of this cancer drug in the Saarc region. We believe that together we will strive to bring new treatment paradigms in cancer care in both Pakistan and India in an affordable way.”

Rawalpindi Chamber of Commerce and Industry President Dr Hassan Sarosh Akram said this would bring a revolution in the lives of poor people who previously could not afford the expensive treatment of cancer.

Opinion

Editorial

Nuclear uncertainty
Updated 23 Oct, 2026

Nuclear uncertainty

With matters frozen in the political and diplomatic spheres, it will take military-to-military engagement to prevent miscalculation in the strategic sphere.
Auto illusion
Updated 23 Oct, 2026

Auto illusion

PAKISTAN’S draft auto policy 2026-31 is ambitious in its targets and directionless in its strategy. It promises...
Two crimes
23 Oct, 2026

Two crimes

THE senseless killing of a teenager by his employers in Multan is a crime that deserves unqualified condemnation. It...
Makkah pact clarity
Updated 22 Oct, 2026

Makkah pact clarity

Fresh aggression can kick off a firestorm that will be in no one’s control, hence it is best to abandon such reckless plans.
Common ground
Updated 22 Oct, 2026

Common ground

Regrettably, the two sides still fail to see the country’s economic, security, and governance crises as challenges that must be solved politically.
The treatment gap
22 Oct, 2026

The treatment gap

A BREAST cancer diagnosis no longer carries the bleak outlook it did a generation ago. Targeted medicines,...